ATE474853T1 - Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren - Google Patents

Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren

Info

Publication number
ATE474853T1
ATE474853T1 AT06789294T AT06789294T ATE474853T1 AT E474853 T1 ATE474853 T1 AT E474853T1 AT 06789294 T AT06789294 T AT 06789294T AT 06789294 T AT06789294 T AT 06789294T AT E474853 T1 ATE474853 T1 AT E474853T1
Authority
AT
Austria
Prior art keywords
immunoglobulin
cells
expression
apoptosis
inhibitor
Prior art date
Application number
AT06789294T
Other languages
English (en)
Inventor
Roland Buelow
Josef Platzer
Original Assignee
Therapeutic Human Polyclonals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals filed Critical Therapeutic Human Polyclonals
Application granted granted Critical
Publication of ATE474853T1 publication Critical patent/ATE474853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AT06789294T 2005-08-03 2006-08-02 Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren ATE474853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70530505P 2005-08-03 2005-08-03
PCT/US2006/030250 WO2007019223A1 (en) 2005-08-03 2006-08-02 Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin

Publications (1)

Publication Number Publication Date
ATE474853T1 true ATE474853T1 (de) 2010-08-15

Family

ID=37309396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06789294T ATE474853T1 (de) 2005-08-03 2006-08-02 Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren

Country Status (9)

Country Link
US (3) US7919672B2 (de)
EP (1) EP1910418B1 (de)
JP (1) JP5188969B2 (de)
CN (3) CN101263158B (de)
AT (1) ATE474853T1 (de)
CA (1) CA2616069C (de)
DE (1) DE602006015653D1 (de)
ES (1) ES2347979T3 (de)
WO (1) WO2007019223A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
WO2008112917A2 (en) * 2007-03-13 2008-09-18 Uti Limited Partnership Peptidyl fluoromethylketones as inhibitors of viral replication
CN112680475A (zh) * 2008-12-18 2021-04-20 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
EP3087177B1 (de) * 2013-12-24 2022-09-14 Kling Biotherapeutics B.V. Ex-vivo-antikörperherstellung
WO2015143284A1 (en) * 2014-03-21 2015-09-24 The General Hospital Corporation Essential fatty acid-producing nonhuman transgenic animals and uses thereof
US10787520B2 (en) * 2015-03-04 2020-09-29 Igm Biosciences, Inc. Multimeric bispecific binding molecules specific for CD20 and CD3
ES2959608T3 (es) * 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
CN108347906A (zh) * 2015-10-29 2018-07-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
KR102598120B1 (ko) * 2016-06-03 2023-11-07 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
CN106480090B (zh) * 2016-10-08 2020-05-12 杭州电子科技大学 一种促进细胞移植和基因表达的转基因载体***及其应用
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
CN111479588A (zh) 2017-12-29 2020-07-31 豪夫迈·罗氏有限公司 用于改善抗vegf抗体的vegf受体阻断选择性的方法
CN111349615A (zh) * 2018-12-24 2020-06-30 上海细胞治疗集团有限公司 制备过表达外源基因的细胞的方法
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
WO2023117834A1 (en) 2021-12-20 2023-06-29 F. Hoffmann-La Roche Ag Agonistic ltbr antibodies and bispecific antibodies comprising them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535501A (ja) * 1999-01-25 2002-10-22 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 多糖繊維
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
WO2004037849A2 (en) * 2002-10-21 2004-05-06 Regents Of The University Of Minnesota Transgenic non-human animals with expanded mature b cell and plasma cell populations

Also Published As

Publication number Publication date
CA2616069A1 (en) 2007-02-15
US8354568B2 (en) 2013-01-15
US20110219465A1 (en) 2011-09-08
US20130102072A1 (en) 2013-04-25
US7919672B2 (en) 2011-04-05
EP1910418B1 (de) 2010-07-21
CN101263158A (zh) 2008-09-10
CN102443058A (zh) 2012-05-09
CN103710371B (zh) 2017-03-01
JP5188969B2 (ja) 2013-04-24
CN103710371A (zh) 2014-04-09
WO2007019223A1 (en) 2007-02-15
US20070033661A1 (en) 2007-02-08
ES2347979T3 (es) 2010-11-26
CA2616069C (en) 2018-07-31
DE602006015653D1 (de) 2010-09-02
CN101263158B (zh) 2011-12-28
EP1910418A1 (de) 2008-04-16
JP2009502203A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
ATE474853T1 (de) Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren
ATE401787T1 (de) Menschliches cd20 exprimierende transgene mäuse
MX2018005389A (es) Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
IL202302A (en) Methods @ for production @ cells @ germ @ non-human @ owners @ site @ ig @ passed @ inactivation L @ animals @ transgenic @ including them and monoclonal antibodies @ produced @ them
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
MX368931B (es) Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
WO2007048077A3 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
PE20120551A1 (es) Anticuerpos contra la angiopoyetina 2 humana
WO2006047367A3 (en) Suppression of endogenous immunoglubolin expression in non-human transgenic animals
SG10201408500RA (en) Antibody producing non-human mammals
SG158158A1 (en) Glp-1 agonists, compositions, methods and uses
EP1947180A4 (de) Transgene seidenraupe mit fähigkeit zur antikörperproduktion und verfahren zur herstellung davon
WO2007117410A3 (en) Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
NZ589411A (en) Method of generating single vl domain antibodies in transgenic animals
HK1162119A1 (en) Animal models and therapeutic molecules
EP4311833A3 (de) Genetisch modifizierte mäuse mit einem haupthistokompatibilitätskomplex
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
EP4249507A3 (de) Transgene mäuse, die chimäre mhc-klasse-ii-moleküle exprimieren
WO2010036976A3 (en) Novel vectors for production of antibodies
FR2856241B1 (fr) Support pour l'aquaculture par bouturage d'animaux aquatiques, notamment destines aux auquariums, et installation comportant un tel support
GB201021451D0 (en) Paralysation of silkworm larvae
TW200518669A (en) Animal model for protease activity and liver damage
DK2097444T3 (da) Fremgangsmåde, der anvender et transgent dyr med forøget immunrespons
ZA200707905B (en) Drought-resistant plants
WO2006072803A3 (en) Antibody

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties